Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson’s Disease

Abstract Background: Choline or bile acids has many beneficial roles in physiological function. However, little was known about growth performance, intestinal mucosal function and microbiota-host interactions of weaned piglets in response to choline or bile acids supplementation. This study aimed to investigate the effect of choline and bile acids mixtures (ChB) supplementation on growth performance, intestinal mucosal barrier function, gut microbiota and bacterial metabolites of weaned piglets. One hundred and twenty-eight crossbred (Duroc × Landrace × Large White) weaned piglets (initial body weight: approximately 8 kg; 21 d of age) were randomly allocated to four different dietary treatments(a control diet (Control) and the other three groups were control diet supplemented with 800 mg/kg choline chloride (choline), 500 mg/kg bile acids (bile acids) or 800 mg/kg choline chloride plus 500 mg/kg bile acids (ChB), respectively) and for 28-d feeding trail. Results: ChB significantly increased average daily gain (ADG) and reduced feed/gain (F/G) ratio, associated with elevation of lipase activity and total bile acids level in ileal digesta compared with control diet. Additionally, ChB altered colonic microbiota by increasing the relative abundance of Lactobacillus and Faecalibacterium , and decreasing the relative abundances of unidentified-Clostridiales , Parabacteroides and Unidentified-Ruminococcaceae , when compared with control diet. Meanwhile, ChB increased the butyrate level and decreased the production of bile acid profiles in the colonic digesta. Besides, feeding ChB improved gut immunity, as reflected by increasing the abundance of IL-10 , FXR and mucin2 transcript, while downregulated expression of TLR4 , MyD88 , NF-κBp65 and TNF-α genes in the intestinal mucosa. Quantitative proteomics of jejunal mucosa further showed that ChB regulated the proteins that were related to inflammatory response. Furthermore, the changes in the ADG and genes expression were associated with alteration of gut microbiota composition and their metabolites. Conclusions: Collectively, our findings demonstrated that choline and bile acids mixture may improve the growth performance and intestinal immune response of weaned piglets through alteration of gut microbiota composition and bacterial metabolites, which promoted gut health.

Download Full-text

Differences in the Composition of Gut Microbiota between Patients with Parkinson’s Disease and Healthy Controls: A Cohort Study

Journal of Clinical Medicine ◽

10.3390/jcm10235698 ◽

2021 ◽

Vol 10 (23) ◽

pp. 5698

Author(s):

Barbara Zapała ◽

Tomasz Stefura ◽

Magdalena Wójcik-Pędziwiatr ◽

Radosław Kabut ◽

Marta Bałajewicz-Nowak ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Gut Microbiota ◽

Demographic Data ◽

Control Group ◽

Healthy Controls ◽

Microbiota Composition ◽

Gastrointestinal Microbiota ◽

The Difference ◽

Generation Sequencing

Gut microbiome and colonic inflammation can be associated with the predisposition and progression of Parkinson’s disease (PD). The presented study aimed to compare gastrointestinal microbiota composition between patients diagnosed with PD and treated only with Levodopa to healthy controls. In this prospective study, patients were recruited in 1 academic hospital from July 2019 to July 2020. The detailed demographic data and medical history were collected using a set of questionnaires. Fecal samples were obtained from all participants. Next-Generation Sequencing was used to assess the microbiota composition. The endpoint was the difference in composition of the gut microbiota. In this study, we enrolled 27 hospitalized PD patients with well-controlled symptoms. The control group included 44 healthy subjects matched for age. Among PD patients, our results presented a higher abundance of Bacteroides phylum, class Corynebacteria among phylum Actinobacteria, class Deltaproteobacteria among phylum Proteobacteria, and genera such as Butyricimonas, Robinsoniella, and Flavonifractor. The species Akkermansia muciniphila, Eubacterium biforme, and Parabacteroides merdae were identified as more common in the gut microbiota of PD patients. In conclusion, the patients diagnosed with PD have significantly different gut microbiota profiles in comparison with healthy controls.

Download Full-text

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease

Frontiers in Neurology ◽

10.3389/fneur.2021.574529 ◽

2021 ◽

Vol 12 ◽

Author(s):

Natalia Palacios ◽

Anas Hannoun ◽

Julie Flahive ◽

Doyle Ward ◽

Kelsey Goostrey ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Gut Microbiota ◽

Beta Diversity ◽

Motor Impairment ◽

Group Iv ◽

Control Group ◽

Microbiota Composition ◽

Two Samples ◽

The Impact

Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of 19 PD patients who had not previously been exposed to Levodopa. Patients provided two stool samples prior to and two samples 90 days after starting Levodopa. Motor impairment (MDS-UPDRS Part III), diet, and other patient characteristics were assessed. 16S rRNA gene amplicon sequencing was used to characterize the microbiota. We examined, cross-sectionally and longitudinally, the associations between Levodopa use and alpha and beta diversity and performed feature-wise, multivariate modeling to identify taxa associated longitudinally with Levodopa use and with improvement in motor function after Levodopa administration.Results: We did not observe significant differences in alpha or beta diversity before vs. after initiation of Levodopa. In longitudinal feature-wise analyses, at the genus level, no taxa were significantly associated with Levodopa use after false discovery rate (FDR) correction (q < 0.05). We observed a marginally lower relative abundance of bacteria belonging to Clostridium group IV in PD patients who experienced a medium or large improvement in motor impairment in response to Levodopa compared to those with a small response [β = −0.64 (SE: 0.18), p-trend: 0.00015 p-FDR: 0.019].Conclusions: In this study, Levodopa was not associated with changes in microbiota composition in this longitudinal analysis. The association between abundance of Clostridium group IV and short-term motor symptom response to Levodopa is preliminary and should be investigated in larger, longer-term studies, that include a control group.

Download Full-text